NEJM publishes Revolution Medicines Phase 1/2 data on RASONQUE™ in NSCLC
Revolution Medicines said The New England Journal of Medicine has published Phase 1/2 clinical data for RASONQUE (daraxonrasib) in metastatic non-small cell lung cancer.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.